[PDF][PDF] EW (2024, pril 25)
M Saleh - from https://hdl. handle. net/1887/3748358 … - scholarlypublications …
Background. Very little knowledge exists on the impact of Alzheimer's disease on the CNS
target site pharmacokinetics (PK). Aim. To predict the CNS PK of cognitively healthy young …
target site pharmacokinetics (PK). Aim. To predict the CNS PK of cognitively healthy young …
Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 …
MAA Saleh, JS Bloemberg, J Elassaiss-Schaap… - Pharmaceutical …, 2022 - Springer
Background Very little knowledge exists on the impact of Alzheimer's disease on the CNS
target site pharmacokinetics (PK). Aim To predict the CNS PK of cognitively healthy young …
target site pharmacokinetics (PK). Aim To predict the CNS PK of cognitively healthy young …
[引用][C] P4‐302: CNS Molecular Gradients in Mild Cognitive Impairment and Alzheimer'S Disease: Implications ror Blood‐Brain Barrier Permeability
LA Daiello, EG Stopa, BR Ott… - Alzheimer's & …, 2016 - Wiley Online Library
Background In health, there is a characteristic CSF-to-serum (C/S) ratio for ions, non-
electrolytes and proteins. The gradients reflect the integrity of the blood-brain barrier (BBB) …
electrolytes and proteins. The gradients reflect the integrity of the blood-brain barrier (BBB) …
The LeiCNS-PK3. 0 model development and applications: healthy-to-diseased CNS pharmacokinetic translation
M Saleh - 2024 - scholarlypublications …
Accurate prediction of the unbound drug concentration-time profile at the CNS target site is
crucial for the assessment of the right drug concentration-effect relationship. PBPK models …
crucial for the assessment of the right drug concentration-effect relationship. PBPK models …
Using the LeiCNS-PK3. 0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in Mice
MAA Saleh, B Gülave, O Campagne, CF Stewart… - Pharmaceutical …, 2023 - Springer
Introduction The unbound brain extracelullar fluid (brainECF) to plasma steady state
partition coefficient, Kp, uu, BBB, values provide steady-state information on the extent of …
partition coefficient, Kp, uu, BBB, values provide steady-state information on the extent of …
Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach
Y Yamamoto, PA Välitalo, YC Wong… - European Journal of …, 2018 - Elsevier
Abstract Knowledge of drug concentration-time profiles at the central nervous system (CNS)
target-site is critically important for rational development of CNS targeted drugs. Our aim was …
target-site is critically important for rational development of CNS targeted drugs. Our aim was …
[HTML][HTML] Effects of reference tissue versus plasma input parametric kinetic modelling on statistical parametric analysis of [11C](R)-PK11195 binding in Alzheimer's …
A Schuitemaker, BNM van Berckel… - Journal of Cerebral …, 2005 - journals.sagepub.com
Methods Thirty [11C](R)-PK11195 studies with on-line arterial sampling were included (8
young (< 40 y) and 12 old controls (> 60 y), and 10 AD patients). Using the on-line whole …
young (< 40 y) and 12 old controls (> 60 y), and 10 AD patients). Using the on-line whole …
[PDF][PDF] Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer's Disease
E Liang, M Green, L Yan, J Wagg… - Alzheimer's and …, 2009 - certara.com
Objectives: ELND005 (scyllo-inositol) is being investigated as an orally administered agent
to treat Alzheimer's Disease (AD). The objective of this analysis was to develop a population …
to treat Alzheimer's Disease (AD). The objective of this analysis was to develop a population …
[引用][C] P2‐011: Pharmacokinetic/Pharmacodynamic Modeling of CSF AB1‐40 Reduction in an Early Alzheimer's Disease Study of JNJ‐54861911, an Oral Bace1 …
A Russu, B Van Broeck, I Tesseur… - Alzheimer's & …, 2016 - Wiley Online Library
Background Data from a Phase 1b study in Early Alzheimer's disease (AD) patients
(prodromal and asymptomatic at risk for AD) treated with JNJ-54861911, an oral BACE1 …
(prodromal and asymptomatic at risk for AD) treated with JNJ-54861911, an oral BACE1 …
Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic …
ECM de Lange, PGM Ravenstijn, D Groenendaal… - The AAPS journal, 2005 - Springer
Our ultimate goal is to develop mechanism-based pharmacokinetic (PK)-pharmacodynamic
(PD) models to characterize and to predict CNS drug responses in both physiologic and …
(PD) models to characterize and to predict CNS drug responses in both physiologic and …